Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | PSIP1 | O75475 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2047195 | 0.84 | PSIP1 (0.52) | KDM4EALDH1A1L3MBTL1PSIP1 | |
| SCHEMBL2053823 | 0.77 | KDM4E (0.33) | KDM4EALDH1A1L3MBTL1PSIP1 | |
| SCHEMBL2053933 | 0.76 | AURKA (0.41) | KDM4EPSIP1 | |
| SCHEMBL6123189 | 0.76 | PSIP1 (0.59) | KDM4EALDH1A1L3MBTL1PSIP1SMN1; SMN2 | |
| SCHEMBL2043361 | 0.73 | PSIP1 (0.54) | PSIP1SMN1; SMN2 | |
| SCHEMBL2042924 | 0.72 | PSIP1 (0.31) | PSIP1 | |
| SCHEMBL2041516 | 0.71 | PDE4A (0.36) | PSIP1 | |
| SCHEMBL2039818 | 0.71 | PSIP1 (0.34) | KDM4EALDH1A1PSIP1SMN1; SMN2 | |
| SCHEMBL2041660 | 0.70 | GSK3B (0.36) | KDM4EALDH1A1L3MBTL1PSIP1SMN1; SMN2 | |
| SCHEMBL2044208 | 0.69 | MAPT (0.47) | KDM4EALDH1A1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2516008-B1 | NOVEL ANTIVIRAL COMPOUNDS | UNIV LEUVEN KATH (BE) | 2014-04-16 | — | — | EP | disclosed |
| US-20120316161-A1 | NOVEL ANTIVIRAL COMPOUNDS | KATHOLIEKE UNIVERSITEIT LEUVEN (BE) | 2012-12-13 | — | — | US | disclosed |
| EP-2516008-A1 | NOVEL ANTIVIRAL COMPOUNDS | Katholieke Universiteit Leuven (BE) | 2012-10-31 | — | — | EP | disclosed |
| WO-2011076765-A1 | NOVEL ANTIVIRAL COMPOUNDS | KATHOLIEKE UNIVERSITEIT LEUVEN (BE) | 2011-06-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120316161-A1 | NOVEL ANTIVIRAL COMPOUNDS | MAVS, EIF2AK2, ZC3HAV1 | KDM4E 2080/4885ALDH1A1 1275/4885L3MBTL1 3305/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.